Over the last 12 months, one TherapeuticsMD, Inc. officers and board members bought shares on the open market, about $14,000 in total, and none of them sold.
Thompson Tommy G (Director) made the biggest buy, worth around $14,000.
45 investment managers listed TXMD in their latest 13F filings (Q2 2026); more funds bought than sold. Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 29, 2025 | Thompson Tommy G | Director | Buy | 8,400 | $1.67 | $14K | SEC |
| Apr 15, 2025 | Thompson Tommy G | Director | Buy | 325 | $1.00 | $325 | SEC |
| Apr 15, 2025 | Walker Marlan D | CEO | Buy | 490 | $1.00 | $490 | SEC |
| Apr 10, 2025 | Walker Marlan D | CEO | Buy | 1,167 | $0.86 | $1K | SEC |
| Apr 10, 2025 | Walker Marlan D | CEO | Buy | 1,136 | $0.87 | $988 | SEC |
| Aug 26, 2024 | Collins Cooper C. | Director | Buy | 4,094 | $1.73 | $7K | SEC |
| Aug 23, 2024 | Collins Cooper C. | Director | Buy | 1,200 | $1.70 | $2K | SEC |
| Dec 7, 2023 | Walker Marlan D | CEO | Sell | 4,550 | $2.24 | $10K | SEC |
| Dec 7, 2023 | Walker Marlan D | CEO | Sell | 14,500 | $2.31 | $33K | SEC |
| May 4, 2023 | Walker Marlan D | CEO | Sell | 692 | $3.64 | $3K | SEC |
| Apr 14, 2023 | Walker Marlan D | CEO | Sell | 1,170 | $3.65 | $4K | SEC |
| Jan 30, 2023 | Donegan Michael C | Officer | Sell | 1,648 | $5.08 | $8K | SEC |
| Jan 30, 2023 | Donegan Michael C | Officer | Sell | 49 | $5.09 | $249 | SEC |
| Jan 25, 2023 | Donegan Michael C | Officer | Sell | 1,302 | $5.34 | $7K | SEC |
| Jan 25, 2023 | Donegan Michael C | Officer | Sell | 7 | $5.31 | $37 | SEC |
In the last 12 months TherapeuticsMD, Inc. insiders made open-market purchases worth about $14,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in TXMD was filed on 2025-12-29.
45 investment managers reported holding TXMD in SEC Form 13F filings for Q2 2026.
No congressional trades in TXMD were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).